FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3103041464> ?p ?o ?g. }

• W3103041464 startingPage "833145" @default.
• W3103041464 abstract "The ability of the human malaria parasite, Plasmodium falciparum to develop resistance against mainstay drugs remains a public health problem. Currently, the antimalarial drugs, lumefantrine (LM), and piperaquine (PQ) are essential components of the mainstay artemisinin-based therapies used for the treatment of malaria globally. Here, we used a model parasite Plasmodium berghei, to investigate the mechanisms of LM and PQ resistance. We employed known resistance reversing agents (RA): probenecid, verapamil, or cyproheptadine to study the mechanisms of LM and PQ resistance in the standard 4-day suppressive test. We then employed reverse genetics to assess the impact of deleting or over-expressing plausible genes associated with the metabolism and transport of drugs. We show that only, cyproheptadine at 5mgkg-1 restored LM activity by above 65% against LM-resistant parasites (LMr) but failed to reinstate PQ activity against PQ-resistant parasites (PQr). Whereas the PQr had lost significant susceptibility to LM, the three RA, cyproheptadine verapamil, and probenecid restored LM potency by above 70%, 60%, and 55% respectively against the PQr. We thus focused on the mechanisms of LM resistance in PQr. Here we show the partial deletion of the cysteine desulfurase (SUFS) and overexpression of the Ferredoxin NADP+ reductase (FNR) genes in the PQr parasite achieved two results; i) abolished the impact of RA on LM activity; ii) restored the susceptibility of PQr to LM alone. Our findings associated SUFS and FNR protein with the action of LM and RA action in P. berghei. We demonstrate that the incorporation of any of the RA into an antimalarial combination that comprises LM would augment LM activity and concomitantly antagonize the emergence of LM resistance derived from PQ pressure. The impact of RA, deletion of SUFS, and overexpression of FNR on LM activity need to be tested in Plasmodium falciparum.nnAuthor summaryLumefantrine (LM) and piperaquine (PQ) are essential drugs for the treatment of malaria globally. Here, we used Plasmodium berghei, a model parasite that infects rodents to study how parasites escape killing by PQ and LM. We first used a second drug: probenecid, verapamil, or cyproheptadine to enhance the activity of LM or PQ. We show that cyproheptadine restores LM activity against LM-resistant parasites (LMr) but failed to reestablish PQ activity against PQ-resistant parasites (PQr). Since PQr is resistant to LM, combining LM with either cyproheptadine, verapamil, or probenecid reinstates LM activity against PQr. We then focused mainly on LM resistance in PQr. After genetically manipulating the PQr, we reveal that cysteine desulfurase (SUFS) and ferredoxin NADP+reductase (FNR) regulate LM capacity to kill parasites. Decreasing the level of SUFS or increasing FNR levels in the PQr makes the parasites susceptible to LM but abolishes the impact of probenecid, verapamil, and cyproheptadine on LM activity. Overall, we provide clues on the link between SUFS and FNR in the action of LM and RA in P. berghei. This study provides a basis for an in-depth analysis of how LM mediates parasites kill and how the parasite escapes LM action in Plasmodium falciparum." @default.
• W3103041464 created "2020-11-23" @default.
• W3103041464 creator A5000715076 @default.
• W3103041464 creator A5002952658 @default.
• W3103041464 creator A5012433995 @default.
• W3103041464 creator A5033576384 @default.
• W3103041464 creator A5040501964 @default.
• W3103041464 creator A5052668734 @default.
• W3103041464 creator A5061350711 @default.
• W3103041464 creator A5063330795 @default.
• W3103041464 creator A5068890011 @default.
• W3103041464 creator A5085728523 @default.
• W3103041464 creator A5088225075 @default.
• W3103041464 date "2019-11-06" @default.
• W3103041464 modified "2023-10-08" @default.
• W3103041464 title "Efficacy of Lumefantrine against piperaquine resistant Plasmodium berghei parasites is selectively restored by probenecid, verapamil, and cyproheptadine through ferredoxin NADP+-reductase and cysteine desulfurase" @default.
• W3103041464 cites W1865107143 @default.
• W3103041464 cites W1969571661 @default.
• W3103041464 cites W1976892175 @default.
• W3103041464 cites W1986191025 @default.
• W3103041464 cites W1988133977 @default.
• W3103041464 cites W1994184498 @default.
• W3103041464 cites W1996418116 @default.
• W3103041464 cites W1996511904 @default.
• W3103041464 cites W2001888038 @default.
• W3103041464 cites W2017652283 @default.
• W3103041464 cites W2025054505 @default.
• W3103041464 cites W2033034230 @default.
• W3103041464 cites W2033634323 @default.
• W3103041464 cites W2034200810 @default.
• W3103041464 cites W2035826427 @default.
• W3103041464 cites W2038964184 @default.
• W3103041464 cites W2047798716 @default.
• W3103041464 cites W2048080607 @default.
• W3103041464 cites W2059401761 @default.
• W3103041464 cites W2061042909 @default.
• W3103041464 cites W2065828976 @default.
• W3103041464 cites W2077074841 @default.
• W3103041464 cites W2079697067 @default.
• W3103041464 cites W2084195880 @default.
• W3103041464 cites W2089692467 @default.
• W3103041464 cites W2105821382 @default.
• W3103041464 cites W2105919772 @default.
• W3103041464 cites W2107522712 @default.
• W3103041464 cites W2108509371 @default.
• W3103041464 cites W2111813303 @default.
• W3103041464 cites W2121975809 @default.
• W3103041464 cites W2123759050 @default.
• W3103041464 cites W2129146050 @default.
• W3103041464 cites W2129930577 @default.
• W3103041464 cites W2132673947 @default.
• W3103041464 cites W2132923209 @default.
• W3103041464 cites W2134967712 @default.
• W3103041464 cites W2135155166 @default.
• W3103041464 cites W2138754677 @default.
• W3103041464 cites W2146216867 @default.
• W3103041464 cites W2147122298 @default.
• W3103041464 cites W2148998009 @default.
• W3103041464 cites W2149191910 @default.
• W3103041464 cites W2149525061 @default.
• W3103041464 cites W2150269854 @default.
• W3103041464 cites W2150454353 @default.
• W3103041464 cites W2154832754 @default.
• W3103041464 cites W2155701533 @default.
• W3103041464 cites W2155791857 @default.
• W3103041464 cites W2159218958 @default.
• W3103041464 cites W2159420567 @default.
• W3103041464 cites W2252923209 @default.
• W3103041464 cites W2336040088 @default.
• W3103041464 cites W2547042202 @default.
• W3103041464 cites W2565054976 @default.
• W3103041464 cites W2573624079 @default.
• W3103041464 cites W2584480708 @default.
• W3103041464 cites W2589856587 @default.
• W3103041464 cites W2613934809 @default.
• W3103041464 cites W2618476115 @default.
• W3103041464 cites W2765137312 @default.
• W3103041464 cites W2767108732 @default.
• W3103041464 cites W2791004613 @default.
• W3103041464 cites W2792643167 @default.
• W3103041464 cites W2796375736 @default.
• W3103041464 cites W2806738725 @default.
• W3103041464 cites W2809263889 @default.
• W3103041464 cites W2890933028 @default.
• W3103041464 cites W2938448257 @default.
• W3103041464 cites W2949451864 @default.
• W3103041464 cites W2951273658 @default.
• W3103041464 cites W2962967773 @default.
• W3103041464 cites W2969593979 @default.
• W3103041464 cites W2978095757 @default.
• W3103041464 cites W2978899862 @default.
• W3103041464 cites W2011495938 @default.
• W3103041464 hasPublicationYear "2019" @default.
• W3103041464 type Work @default.
• W3103041464 sameAs 3103041464 @default.
• W3103041464 citedByCount "0" @default.
• W3103041464 crossrefType "posted-content" @default.
• W3103041464 hasAuthorship W3103041464A5000715076 @default.
• W3103041464 hasAuthorship W3103041464A5002952658 @default.

• next